摘要
本研究采用随机，双盲，平行对照的方法，用长效β１受体阻滞剂塞利洛尔（ｃｅｌｉｐｒｏｌｏｌ）对高血压病进行了为期６周的治疗观察，并与另一β１受体阻滞剂比索洛尔（ｂｉｓｏｐｒｏｌｏｌ）进行对比，同时还进行了自身对照的治疗观察，共有４３２例病人完成此项观察研究，其中对照组２０１例，开放组１９９例，动态血压监测３２例。塞利洛尔的剂量为１００～３００ｍｇ，比索洛尔为５～１０ｍｇ。对照组２０１例患者的观察结果显示：塞利洛尔组总有效率为７８．２％，服药６周后平均收缩压（ＳＢＰ）及舒张压（ＤＢＰ）分别下降１４．２ｍｍＨｇ及１２．６ｍｍＨｇ。比索洛尔组总有效率为８５．０％，ＳＢＰ及ＤＢＰ的下降幅度为１８．２ｍｍＨｇ及１５．９ｍｍＨｇ。两组总有效率无显著差别，不良反应均较少。２４小时动态血压监测显示：用塞利洛尔后总血压负荷明显减少，各时点血压均值明显下降，用两种方法计算的谷／峰比值均大于５０％。研究证实塞利洛尔为一安全有效的抗高血压药物。
A comparative study of Celiprolol (Celi, 100300mg/d) with Bisoprolol (Biso, 510mg/d) was carried out in 432 patients with mild and moderate essential hypertension (EH). Treatment was continued for 6 weeks in a randomized, double blind and single blind design. Total effective rate was 78.2% in Celi group and 85.0% in Biso group. SBP and DBP reductions in Celi group were 14.2 and 12.6 mmHg, and in Biso 18.2 and 15.9mmHg group. There was no significant difference in total effective rate between the two groups. 24hambulatory blood pressure monitory (ABPM) was used in 32 cases. The blood pressure load, mean SBP and DBP in daytime and at night were significantly lower than pretreatment level. The calculated T/P ratios were above 50% (SBP, DBP). In conclusion, celiprolol is effective and well tolerated in treating hypertensive patients.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
1997年第6期426-428,共3页
Chinese Journal of Cardiology
